What's new

Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: P/0053/2024

Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: P/0053/2024

Apr 2, 2025 - 10:09
 0
Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: P/0053/2024
Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: P/0053/2024
Read More

Tags:

Previous Article

NFDA denies accusations of bribery, defends dealers' business model

Next Article

Australia’s solar PV industry hinges on China’s influence

Related Posts

European Shortages Monitoring Platform (ESMP)

European Shortages Monitoring Platform (ESMP)

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Prasugrel Viatris (previously Prasugrel Mylan), prasugrel, Date of authorisation: 15/05/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025  0